Literature DB >> 19086579

Frequent homozygous deletion of p16/CDKN2A gene in malignant gliomas of Iranian patients.

Mohammad Dilmaghani Zadeh1, Reza Amini, Mohsen Firoozray, Pupak Derakhshandeh-Peykar.   

Abstract

Homozygous deletion is the main mechanism of CDKN2A gene inactivation in malignant gliomas. However different frequencies were reported for its deletion. In order to find the homozygous deletion frequency among Iranian patients, we have analyzed the status of CDKN2A gene in 40 malignant gliomas and examined their lalpha and 2 exons by comparative multiplex Polymerase Chain Reaction (PCR), using D9S171 chromosomal marker as an internal control. We found homozygous deletion in 6 out of 7 cases (85.7%) of anaplastic astrocytomas and 20 out of 33 cases (60.6%) of glioblastoma multiforme, in total 26 out of 40 cases (65%) of malignant gliomas. We also found that CDKN2A deleted patients were younger than CDKN2A non-deleted patients and that exon 2 was deleted more than exon 1alpha.

Entities:  

Mesh:

Year:  2007        PMID: 19086579     DOI: 10.3923/pjbs.2007.4246.4250

Source DB:  PubMed          Journal:  Pak J Biol Sci        ISSN: 1028-8880


  3 in total

1.  Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas.

Authors:  Weidong Liu; Guohua Lv; Yawei Li; Lei Li; Bing Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-08-15

2.  Different behaviour of DVL1, DVL2, DVL3 in astrocytoma malignancy grades and their association to TCF1 and LEF1 upregulation.

Authors:  Anja Kafka; Mateja Bačić; Davor Tomas; Kamelija Žarković; Anja Bukovac; Niko Njirić; Goran Mrak; Željka Krsnik; Nives Pećina-Šlaus
Journal:  J Cell Mol Med       Date:  2018-11-23       Impact factor: 5.310

Review 3.  The p53 Pathway in Glioblastoma.

Authors:  Ying Zhang; Collin Dube; Myron Gibert; Nichola Cruickshanks; Baomin Wang; Maeve Coughlan; Yanzhi Yang; Initha Setiady; Ciana Deveau; Karim Saoud; Cassandra Grello; Madison Oxford; Fang Yuan; Roger Abounader
Journal:  Cancers (Basel)       Date:  2018-09-01       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.